Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases
about
JAK2 activation by growth hormone and other cytokinesCrystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617FStructure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinasesAnalysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutationTYK2 kinase activity is required for functional type I interferon responses in vivoMolecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activationMolecular insights into regulation of JAK2 in myeloproliferative neoplasmsThe molecular basis of IL-10 function: from receptor structure to the onset of signaling.The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development.Biology and significance of the JAK/STAT signalling pathways.JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cellsJAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsThe use of structural biology in Janus kinase targeted drug discovery.Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.The Jak/STAT pathway.STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis.The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase.JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules.
P2860
Q27003058-925CE2DC-DAF6-403F-B40F-448A6D6648B4Q27670859-8E43C5E5-CCD8-43AF-B39E-F82FD9665E82Q27679885-DCEE75C6-C80D-45B5-911C-AFF4184203D0Q28477794-EE695543-5FD1-441A-9B00-ACB7ADC20312Q28728338-B3A465B3-B97A-4FAA-9F0A-8517F747794FQ30658298-9768E6C0-D981-44BE-91C5-D172D9F877B3Q33698398-904C5B57-C38B-45A9-8A83-D012A10E4FB7Q33702627-84597109-6F78-4558-BEAC-B670CB7AB5A8Q33843072-2C285657-0D0A-4A81-8D3B-0BB7B64663E6Q35484880-EEDE0684-01A8-4D3E-A3A4-3C7BE44818E3Q35661987-406F8B28-38E1-4FD5-98E9-695FB1A519D0Q35810601-3DF24F9A-A587-48A0-8C54-597137D6581DQ35857092-71760E21-9356-4E0E-BB5F-FA7649AA7F29Q36442514-C66B1169-A72C-42FF-8B2D-8C5D34794CEFQ37146441-ED001D3C-2AD6-498B-89FD-69DBB3C2A3ECQ37168132-EE83D307-628A-419B-919B-4BDC11B22A87Q37168138-F919A8A3-51CB-4A00-A215-47175D45C76FQ37206115-17385627-4EAB-4A07-9807-457C8025AFE2Q37293986-5C7A58D3-50B5-4170-88E2-8888BB0CB5D0Q37921836-AF0EF9AE-4AE7-4974-A805-7B2CC1D2D340Q37989935-3EBA4D2D-6DE1-4424-9691-4109E61EA3ADQ38177821-3F417D16-F3F4-4CDA-8A82-0935E7CAF473Q41681563-947AFA23-3000-44AC-9312-C02531F820D5Q49367076-0A031FA3-9532-46C0-B8E7-377780EE71DFQ50938192-107BFB53-CEC5-406A-96ED-F261F93EB5BF
P2860
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Perspectives for the use of st ...... op inhibitors of Janus kinases
@en
Perspectives for the use of st ...... p inhibitors of Janus kinases.
@nl
type
label
Perspectives for the use of st ...... op inhibitors of Janus kinases
@en
Perspectives for the use of st ...... p inhibitors of Janus kinases.
@nl
prefLabel
Perspectives for the use of st ...... op inhibitors of Janus kinases
@en
Perspectives for the use of st ...... p inhibitors of Janus kinases.
@nl
P2093
P2860
P1476
Perspectives for the use of st ...... op inhibitors of Janus kinases
@en
P2093
Claude Haan
Iris Behrmann
Serge Haan
P2860
P304
P356
10.1111/J.1582-4934.2010.01018.X
P577
2010-01-28T00:00:00Z
2010-03-01T00:00:00Z